Eli Lilly and Company (NYSE:LLY) Shares Sold by Bulltick Wealth Management LLC

Bulltick Wealth Management LLC trimmed its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 60.7% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 1,059 shares of the company's stock after selling 1,637 shares during the period. Bulltick Wealth Management LLC's holdings in Eli Lilly and Company were worth $818,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of LLY. Principal Financial Group Inc. raised its position in Eli Lilly and Company by 5.3% in the third quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company's stock valued at $1,070,698,000 after purchasing an additional 60,306 shares during the period. Nordea Investment Management AB boosted its holdings in Eli Lilly and Company by 13.7% during the 4th quarter. Nordea Investment Management AB now owns 1,154,350 shares of the company's stock valued at $887,014,000 after acquiring an additional 138,835 shares during the period. Legacy Wealth Management LLC MS acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $215,000. CWA Asset Management Group LLC lifted its position in shares of Eli Lilly and Company by 11.9% during the fourth quarter. CWA Asset Management Group LLC now owns 6,794 shares of the company's stock worth $5,245,000 after purchasing an additional 724 shares in the last quarter. Finally, Neville Rodie & Shaw Inc. boosted its position in Eli Lilly and Company by 0.6% in the 4th quarter. Neville Rodie & Shaw Inc. now owns 15,031 shares of the company's stock valued at $11,604,000 after buying an additional 97 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.14% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have commented on LLY shares. Truist Financial increased their price target on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. HSBC cut Eli Lilly and Company from a "buy" rating to a "reduce" rating and cut their price target for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. Hsbc Global Res cut shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. Berenberg Bank set a $970.00 target price on shares of Eli Lilly and Company in a research note on Thursday, January 16th. Finally, Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a research note on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $1,002.80.

Eli Lilly and Company Trading Up 0.2 %

Shares of NYSE:LLY traded up $1.82 during midday trading on Wednesday, reaching $776.94. The company's stock had a trading volume of 3,805,023 shares, compared to its average volume of 3,489,329. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The business has a 50 day moving average price of $820.91 and a 200 day moving average price of $814.03. The firm has a market cap of $736.33 billion, a price-to-earnings ratio of 66.35, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). The firm had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business's revenue was up 45.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.58 earnings per share. Research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.77%. Eli Lilly and Company's dividend payout ratio (DPR) is 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.